Castleark Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Castleark Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Sell	5,076 -220	-4%	-$113K	0.07%	192
2026 Q1	$2.77M	Sell	5,296 -9,170	-63%	-$4.38M	0.09%	187
2025 Q4	$8.42M	Buy	14,466 +4,540	+46%	+$2.32M	0.25%	86
2025 Q3	$4.55M	Buy	+9,926	New	+$3.7M	0.13%	151
2025 Q2	–	Sell	-10,580	Closed	-$3.5M	–	317
2025 Q1	$3.5M	Buy	+10,580	New	+$3.48M	0.12%	153
2024 Q3	–	Sell	-9,130	Closed	-$2.56M	–	294
2024 Q2	$2.56M	Sell	9,130 -80	-0.9%	-$19K	0.1%	162
2024 Q1	$2.46M	Buy	+9,210	New	+$2.17M	0.1%	168
2023 Q3	–	Sell	-9,560	Closed	-$2.21M	–	301
2023 Q2	$2.21M	Buy	+9,560	New	+$2.59M	0.1%	159

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Castleark Management's MDGL Position: Q2 2026 in Review

Castleark Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.2% in Q2 2026, selling an estimated $113K and leaving 5,076 shares worth $2.73M. The position accounts for 0.07% of the portfolio, ranked #192.

Castleark Management first reported a position in MDGL in Q2 2023 and has held it in 8 quarters since. The position peaked at $8.42M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Castleark Management held 5,076 shares of Madrigal Pharmaceuticals worth $2.73M as of Q2 2026.
Castleark Management sold 220 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $113K.
Madrigal Pharmaceuticals made up 0.07% of Castleark Management's portfolio in Q2 2026, its #192 holding.
Castleark Management first reported a position in Madrigal Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Castleark Management's Madrigal Pharmaceuticals position peaked at $8.42M in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.